Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. - Hilberink JR; van Zeventer IA; Chitu DA; Pabst T; Klein SK; Stussi G; Griskevicius L; Valk PJM; Cloos J; van de Loosdrecht AA; Breems D; van Lammeren-Venema D; et al. (Blood cancer journal, 2023)